Navigation Links
Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint

with Hepsera for a median of 49 weeks up to a maximum of 240 weeks. Changes in serum creatinine were observed very commonly in patients pre- and post-transplantation with lamivudine-resistant liver disease and multiple risk factors for changes in renal function who were treated with Hepsera for up to 129 weeks, with a median time on treatment of 19 and 56 weeks, respectively. Clinical and laboratory evidence of exacerbations of hepatitis have occurred after discontinuation of treatment with antiviral therapies for hepatitis B, including Hepsera. Special warnings and precautions for use are included in the package insert regarding monitoring of renal function, post-treatment exacerbations of hepatitis, and the occurrence of lactic acidosis and severe hepatomegaly with steatosis. Dosing instructions for patients with underlying renal impairment and for patients co-infected with HIV are also provided in the package insert, which is available for download online at www.hepsera.com.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia. For more information on Gilead Sciences, please visit the company's website at www.gilead.com or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors, including risks related to Gilead's ability to successfully commercialize tenofovir DF for chronic hepatitis B. For example, the FDA may not approve tenofovir DF for the treatment of chronic hepatitis B in the United States, and marketing approval, i
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:9/2/2014)... , September 2, 2014 ... by Transparency Market Research "Latin America Home Healthcare ... Therapeutic Home Healthcare Devices, Mobility Assist Devices and ... Respiratory Therapy, Infusion Therapy and Unskilled Home Healthcare ... and Forecast, 2014 - 2020" the Latin American ...
(Date:9/2/2014)... , Spanien, September 2, 2014 /PRNewswire/ ... auf dem ESC-Kongress 2014 präsentierte GARFIELD-AF-Register ... und Behandlungsergebnisse von schlaganfallgefährdeten Patienten in ... Die Daten der ... einer innovativen und unabhängigen Forschungsinitiative zur ...
(Date:9/2/2014)... 2, 2014 Particle Sciences, the leading CDMO ... in development and manufacturing capabilities with the addition of ... , Particle Sciences, Associate Director Clinical Production, "The company ... room square footage, equipment and staff across the board, ... now has over 6000ft 2 of operating cleanroom ...
Breaking Medicine Technology:Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 2Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 3Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 4Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 5Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 6Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 3Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 4Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 5Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 6Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 7Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 8Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 9Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 10Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 11Particle Sciences Expands Drug Eluting Device Capabilities and Overall Clinical Trial Manufacturing Resources 2
... (NASDAQ: AMRI ), a global contract services organization ... as part of its ongoing global operations review to improve ... its European operations focused on a reduction of the workforce ... at its Budapest, Hungary operation. As a ...
... Jan. 9, 2012  Xenon today announced a strategic alliance ... RO, ROG; OTCQX: RHHBY), to discover and develop compounds ... "We are delighted to be collaborating with ... "Genentech is among the world,s leading biotech companies and ...
Cached Medicine Technology:AMRI Announces Review of Its Hungary Operation 2AMRI Announces Review of Its Hungary Operation 3Xenon to Collaborate with Genentech on Discovery of Novel Targeted Pain Therapeutics 2
(Date:9/2/2014)... 02, 2014 Welcome to Arthritis ... 4.6 million Canadians living with the disease, The Arthritis ... Arthritis” video series featuring well-known Canadians from different walks ... ,      Lloyd Robertson , veteran news anchor ... skier ,      Amy Cotton , two-time ...
(Date:9/2/2014)... prevalence of opioid-involved overdoses has become an increasing concern ... to the New York City Department of Health and ... in 2011 was nearly triple the number of such ... attributed to a dramatic rise in nonmedical prescription opioid ... recently, in heroin use among youth who transitioned from ...
(Date:9/2/2014)... research studies have made it clear that a mother,s ... lactation have a profound impact on her offspring and ... However, until now, the mechanisms behind this phenomenon were ... 2014 issue of The FASEB Journal F ... link between a mother,s diet and an offspring,s risk ...
(Date:9/2/2014)... PA (PRWEB) September 02, 2014 ... communications and education, is proud to announce the acquisition ... clinical resource center designed for healthcare professionals who integrate ... offers practitioners comprehensive access to:, , ... Dedicated topic centers for diabetes, oncology, renal ...
(Date:9/2/2014)... ROCHESTER, Minn. How well patients recover from ... their medical conditions and the operations themselves. Family ... risk of surgical complications, a Mayo Clinic study ... operation may reduce patients, stress, speed their recoveries ... The study specifically looked at colon cancer patients, ...
Breaking Medicine News(10 mins):Health News:‘Voices of Arthritis’ Launches Awareness Month 2Health News:‘Voices of Arthritis’ Launches Awareness Month 3Health News:NYC teens and young adults who abuse prescription at high risk for overdose 2Health News:NYC teens and young adults who abuse prescription at high risk for overdose 3Health News:How genes link a mother's diet to the risk of obesity in her offspring 2Health News:HMP Communications Holdings, LLC, Acquires Nutrition411.com 2Health News:Family conflicts, other non-physical worries before cancer surgery raise patients' complication risk 2
... time you load on the sauce, onto your pizza or spaghetti, ... ones//. , Scientists from Ohio State University have ... tomatoes, is absorbed better by the body, when it comes from ... study is published in the Journal of Agricultural and Food Chemistry. ...
... Defense Services will be bound by a Supreme Court order ... fired due to their health condition. , ,Last week ... soldiers and naval officers with HIV or AIDS. They could ... unsuitable for work. ,Senior officials in the army ...
... that the hormone glucocorticoids may not be as beneficial ... prescribed by many specialists as a thrust to infertility ... glucocorticoids are employed by many specialists to treat infertility, ... responses in a good manner. They are used to ...
... Remanence of anthrax spores in Smailholm and the border ... a decontamination operation// at a village hall where drumming ... deputed the New York-based specialists Sabre, to look into ... of anthrax evident in certain areas in Northumberland and ...
... accident that left a father and young daughter dead in ... ,Two people were killed Monday after the single-engine ... a small local airport in Bedford - into the home ... of the former mother-in-law of the divorced 47-year-old pilot, The ...
... who was seen visibly limping at a film awards function ... film 'Drona' in Bikaner last month. ,'She ... ignored it and kept shooting right through the injury. Because ... Filmfare awards show and even in parliament,' Amitabh Bachchan, Jaya's ...
Cached Medicine News:Health News:Pass the Orange Tomato Sauce Please 2
The True Non-Compliant Balloon....
... Jude Medical® Pacing System Analyzer (PSA Wand), ... implantation testing, programming and interrogation of bradycardia ... easy-to-use accessory to the St. Jude Medical ... obtaining measurements of intrinsic P- and R-wave ...
... The Finnpipette BioControl multichannel ... features as the single ... handle fits all seven ... channel tip cone modules. ...
... Long series in colonies, rows, and microplatesthat ... the multichannel pipette is becoming an ever-increasing ... use) was the main reason that the ... 8- or 12-channel pipette provides effective, precise, ...
Medicine Products: